This complicates the application of AAV-mediated gene therapy for disorders resulting in hepatocyte damage, such as Fumarylacetoacetate hydrolase (FAH) deficiency and PFIC. This evidence concerns the gene ATP8B1 and hyperinsulinemic hypoglycemia, familial, 4.